A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

This is a randomized, blinded, placebo-controlled, phase 1 clinical trial to evaluate the safety and immunogenicity of CVM150 and CVM26 in healthy adults who received the recommended 2 doses of mumps vaccine (as measles-mumps-rubella \[MMR\] or MMR -varicella \[MMRV\]) in childhood. Number of Participants: A total of up to 60 participants, aged 18-29 years, are planned to be enrolled. Treatment Assignment: All participants will be randomized to receive a single intranasal dose of CVM150, CVM26 or intranasal saline placebo (1:1:1) on Day 1. Study visits: Participants will be asked to complete approximately 6-8 clinic visits, over a period of approximately 12 months duration per participant.